Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say
• By The Pink Sheet
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
